Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Mark Glickman

Mark Glickman is recorded as CEO at TherapeuticsMD, Inc. (TXMD). TherapeuticsMD, Inc. reported in an 8-K filed September 12, 2022 that Mark Glickman was appointed Interim Co-Chief Executive Officer, effective September 6, 2022. The proxy statement of the company reports total compensation of $2,353,579 for Mark Glickman in fiscal 2020, including a base salary of $453,409. Disclosed compensation is on record for 3 fiscal years.

“On September 6, 2022, the board of directors (the "Board") of TherapeuticsMD, Inc., a Nevada corporation (the "Company"), appointed Dr. Brian Bernick, the Company's co-founder and Chief Scientific and Medical Officer, and Mr. Mark Glickman, the Company's Chief Business Officer, as the Company's Interim Co-Chief Executive Officers and co-principal executive officers.”
TherapeuticsMD, Inc. Form 8-K, filed September 12, 2022 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Company

Leadership on record at TherapeuticsMD, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2020 — $453,409 $2,353,579
2019 — $440,000 $624,392
2018 — $322,500 $9,014,658

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.